Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Nuvalent Announced Cancer Discovery Publication Highlighting Design, Preclinical Activity, and Early Clinical Data of ALK-Selective Inhibitor NVL-655
Baird Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $105
Baird analyst Colleen M. Kusy maintains $Nuvalent(NUVL.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 34.5% and a total
Jefferies Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $97
Jefferies analyst Roger Song maintains $Nuvalent(NUVL.US)$ with a buy rating, and maintains the target price at $97.According to TipRanks data, the analyst has a success rate of 32.4% and a total
Piper Sandler Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100
Piper Sandler analyst Christopher Raymond maintains $Nuvalent(NUVL.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 53.0%
Nuvalent Price Target Maintained With a $99.00/Share by Wedbush